Onconetix, Inc. (ONCO)
| Market Cap | 3.32M -22.8% |
| Revenue (ttm) | 645,824 -51.3% |
| Net Income | -10.20M |
| EPS | -17.16 |
| Shares Out | 3.95M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,261,950 |
| Open | 0.8611 |
| Previous Close | 1.0200 |
| Day's Range | 0.8200 - 0.9500 |
| 52-Week Range | 0.5868 - 209.5000 |
| Beta | 2.68 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2026 |
About ONCO
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men’s health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test. The company was formerly known as Bl... [Read more]
Financial Performance
In 2025, Onconetix's revenue was $815,371, a decrease of -67.70% compared to the previous year's $2.52 million. Losses were -$15.53 million, -73.63% less than in 2024.
Financial StatementsNews
Onconetix Acquisition Target Realbotix Launches Pilot with Leading European Telecommunications Company to Deploy Humanoid Robots in Live Presentations and Events
Pilot Tests Humanoid Robots as Presenters, Hosts, and Brand Ambassadors Before Live Audiences, Extending Robot Capabilities Beyond One-on-One Interaction into Dynamic, Audience-Facing Environments; On...
Onconetix Registration statement: Registration filing
Onconetix filed a registration statement on August 31, 2026, providing details about a securities offering with the SEC.
Onconetix registers to sell 100M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 100M shares of common stock. The company is not selling any…
Onconetix Quarterly report: Q2 2026
Onconetix has published its Q2 2026 quarterly earnings report on August 13, 2026.
Onconetix Registration statement: Registration filing
Onconetix filed a registration statement on August 12, 2026, providing details about a securities offering with the SEC.
Onconetix Acquisition Target Realbotix Secures Agreement for Humanoid Robot Appearance on Emmy Award-Winning Streaming Series
Entertainment Industry Agreement Reflects Real-World Adoption of Humanoid Robotics Technology Across Education, Healthcare, Hospitality, and Customer Engagement; Onconetix Recently Entered into a Defi...
Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG
Proteomedix Co-Founder and Proclarix® Co-Developer Returns to Company's Board; Thomas Meier, PhD Re-Elected as Chairman at Annual General Meeting CINCINNATI, Ohio , Aug. 05, 2026 (GLOBE NEWSWIRE) -- O...
Onconetix Highlights Realbotix Partnership with Bloom Services to Launch UK Pilot Using Humanoid Robots to Combat Elderly Social Isolation
Realbotix Robots and AI to Deploy in Evidence-Based Pilot Designed to Improve Wellbeing and Address Loneliness Among Older Adults in UK Care Settings; Realbotix Becomes Accredited Supplier on Bloom's ...
Onconetix Highlights Realbotix's Launch of Humanoid Robot and AI Teachers Assistant Pilot Program in New York State School District
Salamanca City Central School District on Seneca Nation Reservation to Deploy Optio and Realbotix M-Series Humanoid Robot; Pilot to Expand to Approximately 500 High School Students in Fall 2026; Oncon...
Onco-Innovations Announces Non-Brokered LIFE Offering
Not for distribution to United States wire services or for dissemination in the United States VANCOUVER, BC / ACCESS Newswire / June 19, 2026 / Onco-Innovations Limited (CBOE:ONCO) ("Onco" or the "Com...
Onco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling Development
Also Announces Appointment of Mr. Dave Antony as CFO VANCOUVER, BC / ACCESS Newswire / June 19, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H) (WKN:A3EKSZ) ("Onco" or the "...
Onco-Innovations Completes Project with Kuano, Using Their Quantum-Based Platform to Deliver Insights for PNKP Inhibitor Technology Optimization
VANCOUVER, BC / ACCESS Newswire / June 16, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce, further to its news...
Onconetix Registration statement: Registration filing
Onconetix filed a registration statement on June 9, 2026, providing details about a securities offering with the SEC.
Onconetix files to sell 100M shares of common stock for holders
06:02 EDT Onconetix (ONCO) files to sell 100M shares of common stock for holders
Onconetix Inc trading halted, news pending
19:50 EDT Onconetix (ONCO) Inc trading halted, news pending
Onconetix announces 1-for-10 reverse stock split
Onconetix (ONCO) announced that its board of directors has approved a 1-for-10 reverse stock split of its outstanding shares of common stock, to be effective as of 12:01 a.m. Eastern…
Onconetix, Inc. Announces 1-for-10 Reverse Stock Split
CINCINNATI, Ohio, May 19, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and com...
Realbotix expects transaction with Onconetix to close by October
Realbotix (XBOTF) provided an update on its previously announced transaction to list Realbotix LLC on the Nasdaq Capital Market via a reverse takeover transaction with Onconetix (ONCO). The proposed t...
Realbotix Provides Update on Nasdaq Listing
LAS VEGAS--(BUSINESS WIRE)--Realbotix Corp. (TSX-V: XBOT) (Frankfurt: 76M0.F) (OTC: XBOTF) (“Realbotix” or the “Parent Company”), a leading AI humanoid robot manufacturer for social tasks, is pleased ...
Onconetix Reports Q1 2026 Progress at Proteomedix AG, Including Two New Peer-Reviewed Publications and Initiation of U.S. Validation Study
New Clinical Data Reinforce Proclarix® Performance in Reducing Overdiagnosis and Unnecessary Biopsies; Multi-Center PRIME Study Initiated in Collaboration with Labcorp; European Commercial Expansion A...
Onconetix Quarterly report: Q1 2026
Onconetix has published its Q1 2026 quarterly earnings report on May 13, 2026.
Onconetix Earnings release: Q1 2026
Onconetix released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Onconetix Registration statement: Registration filing
Onconetix filed a registration statement on May 7, 2026, providing details about a securities offering with the SEC.
Onconetix files to sell 25M shares of common stock for holders
16:12 EDT Onconetix (ONCO) files to sell 25M shares of common stock for holders
Onconetix Registration statement: Registration filing
Onconetix filed a registration statement on April 28, 2026, providing details about a securities offering with the SEC.